Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer

Award Number: K08CA259621
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/01/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer - PROJECT SUMMARY/ABSTRACT Pancreatic adenocarcinoma (PDAC) carries a dismal prognosis and remains a critical unmet public health need. The recent recognition that a subset of pancreas cancer harbors potential neoantigens has intensified interest in defining the molecular and cellular mechanisms of immune evasion in PDAC to guide effective therapeutic strategies that leverage the adaptive immune system in this disease. However, difficulty in precisely defining the tumor-reactive T cell compartment has hampered prior efforts to delineate the full spectrum of mechanisms by which PDAC evades immune eradication. I hypothesize that a subset of PDAC escapes immune surveillance through dysfunction and/or altered localization of tumor-reactive T cells. Our preliminary studies, using neoantigen-expressing preclinical models of PDAC to evaluate tumor-specific immune responses, have revealed that a significant subset of tumors acquire the ability to evade immune clearance and that neoantigen-specific cos• tumor-infiltrating lymphocytes (TILs) adopt multiple states of dysfunction. Additionally, we recently demonstrated that the CD155/TIGIT axis both promotes and maintains immune evasion in PDAC (Freed-Pastor et al. Cancer Cell, in press). In this proposal, I leverage recently developed preclinical models, advances in single-cell profiling, and highly multiplexed imaging modalities to interrogate the cytotoxic T cell compartment in murine and human PDAC. Specifically, I will evaluate the effects of TIGIT/PD-1 co-blockade plus CD40 agonism on the tumor-immune microenvironment in PDAC using single-cell transcriptomic and highly multiplexed immunofluorescence technologies. I will also utilize flow cytometry and multiplexed imaging to investigate the spatiotemporal dynamics of T cell phenotypes and localization during tumor progression in preclinical models, and compare T cell responses to different neoantigens. Furthermore, I will perform high-resolution profiling on TILs isolated directly from pancreas cancer patients. Collectively, these studies hold tremendous promise for accelerating effective immune-based therapies for PDAC. The proposed research will be performed at the Koch Institute for Integrative Cancer Research at MIT, under the guidance of Dr. Tyler Jacks, an international leader in cancer biology and tumor immunology, with co-mentorship by Dr. Brian Wolpin, a leading pancreas cancer researcher at the Dana-Farber Cancer Institute. Importantly, this research strategy is one part of a comprehensive training program to support my transition to an independent research career in basic and translational cancer biology and tumor immunology. My scientific advisors (Drs. Arlene Sharpe, Stefani Spranger, and Osama Rahma) are distinguished experts with experience highly relevant to the proposed research. My long-term goal is to lead an independent academic research group, focused on deciphering the molecular and cellular mechanisms by which PDAC evades immune clearance, such that these insights can be used to guide therapeutic strategies to combat pancreas cancer and other cancers. The K08 award will provide pivotal protected time for continued mentored research and enable a successful transition to independence.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $230,972 )
2026	2026	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Research Manpower	000	5	6/5/2026	NON-COMPETING CONTINUATION	$230,972
														Subtotal = $230,972

Issue Date FY: 2025 ( Subtotal = $230,971 )
2025	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Research Manpower	000	4	5/20/2025	NON-COMPETING CONTINUATION	$230,971
														Subtotal = $230,971

Issue Date FY: 2024 ( Subtotal = $211,308 )
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Research Manpower	000	3	6/5/2024	NON-COMPETING CONTINUATION	$211,308
														Subtotal = $211,308

Issue Date FY: 2023 ( Subtotal = $211,308 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Research Manpower	000	2	7/14/2023	NON-COMPETING CONTINUATION	$211,308
														Subtotal = $211,308

Issue Date FY: 2022 ( Subtotal = $211,308 )
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Research Manpower	000	1	6/15/2022	NEW	$211,308
														Subtotal = $211,308

Grand Total All Awards = $1,095,867

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer

Award Number: K08CA259621

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/01/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer